These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11923792)

  • 1. Cost and cost-effectiveness studies in heart failure research.
    Weintraub WS; Cole J; Tooley JF
    Am Heart J; 2002 Apr; 143(4):565-76. PubMed ID: 11923792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic significance of heart failure. An overview of costs and economics of therapy].
    Szucs TD; Sokolovic E
    Herz; 2000 Aug; 25(5):538-46. PubMed ID: 10993002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data.
    Boyko WL; Glick HA; Schulman KA
    Am Heart J; 1999 May; 137(5):S115-9. PubMed ID: 10220611
    [No Abstract]   [Full Text] [Related]  

  • 11. Digoxin therapy: A persisting interest despite contrary winds.
    Juillière Y; Selton-Suty C
    Arch Cardiovasc Dis; 2010 May; 103(5):281-4. PubMed ID: 20619237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of heart decompensation using angiotensin converting enzyme inhibitors. Pharmaco-economic aspects].
    Kulbertus H
    Rev Med Liege; 1998 May; 53(5):255-8. PubMed ID: 9689878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Issues in Heart Failure in the United States.
    Heidenreich PA; Fonarow GC; Opsha Y; Sandhu AT; Sweitzer NK; Warraich HJ;
    J Card Fail; 2022 Mar; 28(3):453-466. PubMed ID: 35085762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective management of heart failure.
    Parmley WW
    Clin Cardiol; 1996 Mar; 19(3):240-2. PubMed ID: 8674263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of treating heart failure.
    Mark DB
    Am J Cardiol; 1997 Oct; 80(8B):33H-38H. PubMed ID: 9372996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs.
    Skrepnek GH; Abarca J; Malone DC; Armstrong EP; Shirazi FM; Woosley RL
    Ann Pharmacother; 2005 Nov; 39(11):1785-91. PubMed ID: 16219900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expectations for management of heart failure: current recommendations.
    Abraham WT; Scarpinato L
    J Am Board Fam Pract; 2002; 15(1):39-49. PubMed ID: 11841137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in clinical practice: the case of heart failure.
    Rich MW; Nease RF
    Arch Intern Med; 1999 Aug 9-23; 159(15):1690-700. PubMed ID: 10448770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure.
    Ward RE; Gheorghiade M; Young JB; Uretsky B
    J Am Coll Cardiol; 1995 Jul; 26(1):93-101. PubMed ID: 7797781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.